Similar articles

• Vascular brachytherapy boon or bust?

  Kereiakes DJ, Willerson JT. Kereiakes DJ, et al. Circulation. 2003 Jul 29;108(4):389-90. doi: 10.1161/01.CIR.0000084892.95826.0A. Circulation. 2003. PMID: 12885732 Review. No abstract available.
• Coronary brachytherapy in the drug-eluting stent era: don't bury it alive.

  Waksman R, Weinberger J. Waksman R, et al. Circulation. 2003 Jul 29;108(4):386-8. doi: 10.1161/01.CIR.0000082928.33891.B7. Circulation. 2003. PMID: 12885731 Review. No abstract available.
• The future of CART in the era of drug eluting stents: "It's not over until it's over". Counterpoint.

  Tripuraneni P. Tripuraneni P. Brachytherapy. 2003;2(2):74-6. doi: 10.1016/S1538-4721(03)00104-1. Brachytherapy. 2003. PMID: 15062143 No abstract available.
• One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent in patients with diabetes mellitus.

  Finn AV, Gold HK. Finn AV, et al. Circulation. 2004 Sep 21;110(12):e318-9; author reply e318-9. doi: 10.1161/01.CIR.0000142207.05425.76. Circulation. 2004. PMID: 15381668 No abstract available.
• Intravascular brachytherapy versus drug-eluting stents for the treatment of patients with drug-eluting stent restenosis.

  Torguson R, Sabate M, Deible R, Smith K, Chu WW, Kent KM, Pichard AD, Suddath WO, Satler LF, Waksman R. Torguson R, et al. Am J Cardiol. 2006 Nov 15;98(10):1340-4. doi: 10.1016/j.amjcard.2006.06.027. Epub 2006 Sep 26. Am J Cardiol. 2006. PMID: 17134625